Capricor Therapeutics マネジメント

マネジメント基準チェック /44

Capricor Therapeuticsの CEO はLinda Marbánで、 Jan2010年に任命され、の在任期間は 14.83年です。の年間総報酬は$ 747.32Kで、 29.5%給与と70.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.44%を直接所有しており、その価値は$ 3.72M 。経営陣と取締役会の平均在任期間はそれぞれ12.7年と11年です。

主要情報

Linda Marbán

最高経営責任者

US$747.3k

報酬総額

CEO給与比率	29.5%
CEO在任期間	14.8yrs
CEOの所有権	0.4%
経営陣の平均在職期間	12.7yrs
取締役会の平均在任期間	11yrs

経営陣の近況

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

CEO報酬分析

Capricor Therapeutics の収益と比較して、Linda Marbán の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$34m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$747k	US$221k	-US$22m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$1m	US$210k	-US$29m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$23m
Dec 31 2021	US$2m	US$200k	-US$20m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$2m	US$150k	-US$14m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$229k	US$157k	-US$8m
Sep 30 2019	n/a	n/a	-US$9m
Jun 30 2019	n/a	n/a	-US$12m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$377k	US$233k	-US$15m
Sep 30 2018	n/a	n/a	US$374k
Jun 30 2018	n/a	n/a	US$2m
Mar 31 2018	n/a	n/a	US$2m
Dec 31 2017	US$602k	US$233k	US$2m

報酬と市場: Lindaの総報酬 ($USD 747.32K ) は、 US市場 ($USD 3.17M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Lindaの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Linda Marbán (61 yo)

14.8yrs

在職期間

US$747,315

報酬

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frank Litvack	Executive Chairman of the Board	12.8yrs	US$759.55k	0.29% $ 2.5m
Linda Marbán	Co-Founder	14.8yrs	US$747.32k	0.44% $ 3.7m
Anthony Bergmann	CFO & Corporate Treasurer	6.8yrs	US$730.85k	0.0052% $ 44.4k
Karen Krasney	Executive VP	12.7yrs	US$740.77k	0.044% $ 373.3k
Kristi A. Elliott	Chief Science Officer	no data	データなし	データなし
Catherine Kelleher	Consultant	no data	データなし	データなし

12.7yrs

平均在職期間

64.5yo

平均年齢

経験豊富な経営陣: CAPRの経営陣は経験豊富で経験豊富です（平均在職期間は12.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Frank Litvack	Executive Chairman of the Board	12.8yrs	US$759.55k	0.29% $ 2.5m
Linda Marbán	Co-Founder	11yrs	US$747.32k	0.44% $ 3.7m
George Dunbar	Independent Director	11yrs	US$211.13k	0.023% $ 196.6k
Earl Collier	Independent Director	11yrs	US$222.37k	0.13% $ 1.1m
David Musket	Independent Director	11yrs	US$237.36k	0.20% $ 1.7m
Francesco Muntoni	Member of Scientific Advisory Board	no data	データなし	データなし
Pat Furlong	Member of Scientific Advisory Board	no data	データなし	データなし
Eugenio Mercuri	Member of Scientific Advisory Board	no data	データなし	データなし
Craig McDonald	Member of Scientific Advisory Board	no data	データなし	データなし
Oscar Mayer	Member of Scientific Advisory Board	no data	データなし	データなし
Michelle Eagle	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Taylor	Member of Scientific Advisory Board	6.8yrs	データなし	データなし

11.0yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: CAPRの取締役会は経験豊富で経験豊富です ( 11年の平均在任期間)。

Capricor Therapeutics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024

Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors

Insufficient new directors

Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors

Capricor Therapeutics, Inc Announces Board Changes

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024

New major risk - Shareholder dilution

Capricor Therapeutics, Inc. Intends to File A Biologics License Application

Capricor Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.004 million.

Capricor Therapeutics Announces Positive Long-Term Data from Hope-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Price target increased by 28% to US$25.40

Forecast to breakeven in 2026

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Capricor Therapeutics, Inc. announced that it has received $14.999998 million in funding from Nippon Shinyaku Co., Ltd.

Consensus revenue estimates fall by 16%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

New major risk - Financial position

Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Profitability

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 24%, EPS downgraded

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Capricor Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024

Consensus revenue estimates increase by 41%

Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

New major risk - Financial position

Capricor Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Consensus revenue estimates fall by 51%

New minor risk - Market cap size

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors

New minor risk - Share price stability

Consensus revenue estimates increase by 86%

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insufficient new directors

Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors

Capricor Therapeutics, Inc Announces Board Changes

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Business Officer exercised options and sold US$51k worth of stock

Independent Director notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

Forecast to breakeven in 2025

Now 26% undervalued after recent price drop

Consensus revenue estimates increase by 146%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Forecast to breakeven in 2024

マネジメント基準チェック /44